Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 8:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 882 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Period C Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Rectal Microbicide Acceptability, Tolerability and Adherence

NCT03671239
View directory record Official record
Conditions
HIV Prevention
Interventions
Placebo rectal insert, Placebo rectal suppository, Placebo rectal douche
Behavioral
Lead sponsor
Microbicide Trials Network
Network
Eligibility
18 Years to 35 Years
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Birmingham, Alabama • San Francisco, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 31, 2026, 8:31 AM EDT
Active, not recruiting Not applicable Interventional

Diet and Health in Adults With Metabolic Syndrome

NCT03935048
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Higher protein, low glycemic load diet
Dietary Supplement
Lead sponsor
University of Arkansas, Fayetteville
Other
Eligibility
18 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 31, 2026, 8:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

High Level Pulsed Heat Versus Low Level Steady Heat in Subjects With Chronic Low Back Pain

NCT04109703
View directory record Official record
Conditions
Chronic Pain, Low Back Pain, Heat, Analgesia
Interventions
High Level Pulsed Heat delivered by Generation 5 devices from Soovu Labs Inc., Low Level (37 degrees C) delivered by the control device Generation 5 devices from Soovu Labs Inc.
Device
Lead sponsor
Soovu Labs Inc.
Industry
Eligibility
21 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Oct 31, 2026, 8:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Participants

NCT03682380
View directory record Official record
Conditions
Healthy
Interventions
Seltorexant High Dose, Seltorexant Low Dose
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 31, 2026, 8:31 AM EDT
Completed Phase 1 Interventional

New Treatment Option for Pancreatic Cancer

NCT01364805
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Intravenous Vitamin C, Gemcitabine
Drug
Lead sponsor
Jeanne Drisko, MD, CNS, FACN
Other
Eligibility
21 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 31, 2026, 8:31 AM EDT
Active, not recruiting Phase 3 Interventional

Tele-Collaborative Outreach to Rural Patients With Chronic Pain

NCT06091202
View directory record Official record
Conditions
Chronic Pain
Interventions
CORPs Intervention, Minimally Enhanced Usual Care (MEUC)
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Minneapolis, Minnesota • Portland, Oregon • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 31, 2026, 8:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

NCT02657343
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, T-DM1, Trastuzumab, Fulvestrant
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 31, 2026, 8:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy Participants

NCT03127189
View directory record Official record
Conditions
Healthy
Interventions
Rilpivirine, Rilpivirine Long-acting Parenteral Formulation
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 31, 2026, 8:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers

NCT02214433
View directory record Official record
Conditions
Bacterial Infections
Interventions
Placebo IV Solution, Debio 1450 IV Solution, Placebo Tablet or Capsule, Debio 1450 Tablet, Debio 1450 Capsule, Debio 1450 Oral Solution, Pantoprazole
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Oct 31, 2026, 8:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants

NCT05136404
View directory record Official record
Conditions
Healthy
Interventions
Selpercatinib
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 31, 2026, 8:31 AM EDT
Completed Phase 3 Interventional Results available

Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A

NCT01029340
View directory record Official record
Conditions
Blood Coagulation Disorders, Hemophilia A
Interventions
Recombinant Factor VIII (BAY81-8973), Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Biological
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
7
States / cities
Orange, California • Sacramento, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 31, 2026, 8:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Addressing Mental Health in African American Job Training Adolescents and Young Adults

NCT00979524
View directory record Official record
Conditions
Depression
Interventions
Comprehensive Mental Health Services and Supports
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
16 Years to 24 Years
Enrollment
782 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Oct 31, 2026, 8:31 AM EDT
Recruiting Phase 2 Interventional

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

NCT05645718
View directory record Official record
Conditions
Leukemia
Interventions
Cyclophosphamide, Vincristine, Blinatumomab, Methotrexate, Cytarabine, Mercaptopurine, Prednisone, Pegfilgrastim, Inotuzumab ozogamicin, Rituximab, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 25 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 31, 2026, 8:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults

NCT06290050
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Midazolam, Repaglinide, TAK-279
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 31, 2026, 8:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2484595 on Pharmacokinetics in Healthy Participants

NCT01448824
View directory record Official record
Conditions
Healthy Participants
Interventions
LY2484595, Placebo, Ketoconazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 31, 2026, 8:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study in Healthy Male Subjects for ZD4054 (Zibotentan) Immediate Release Tablets.

NCT00713791
View directory record Official record
Conditions
Healthy
Interventions
ZD4054
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 15, 2010 · Synced Oct 31, 2026, 8:31 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional Accepts healthy volunteers

Aerobic Exercise After Traumatic Brain Injury

NCT05786729
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Aerobic Exercise (AER), Rehabilitation
Other
Lead sponsor
Centre for Neuro Skills
Industry
Eligibility
18 Years to 60 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Bakersfield, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 31, 2026, 8:31 AM EDT
Completed Phase 2 Interventional Results available

Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.

NCT03257995
View directory record Official record
Conditions
Asthma
Interventions
Indacaterol maleate, Indacaterol acetate, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
North Dartmouth, Massachusetts • St Louis, Missouri • Skillman, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 31, 2026, 8:31 AM EDT
Completed Phase 3 Interventional Results available

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

NCT00623428
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
38
States / cities
Birmingham, Alabama • La Jolla, California • Lancaster, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 31, 2026, 8:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Understand How a Study Medicine Called PF-07328948 is Absorbed and Processed in the Body of Healthy Male Adults

NCT07508228
View directory record Official record
Conditions
Healthy
Interventions
Oral [14C]PF-07328948, Oral Unlabeled PF-07328948, IV [14C]PF-07328948
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 31, 2026, 8:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus

NCT06279234
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Obesity
Interventions
Placebo, Rosuvastatin, Midazolam, Omeprazole, PF-06954522
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Anaheim, California • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 31, 2026, 8:31 AM EDT
Completed Phase 1 Interventional Results available

Study of MLN8237 in Participants With Advanced Solid Tumors

NCT00962091
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Alisertib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 31, 2026, 8:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers

NCT00404274
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Casopitant (GW679769) oral tablets, Warfarin oral tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
Gainesville, Florida • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 31, 2026, 8:31 AM EDT
Completed Phase 1 Interventional

Concurrent vs. Sequential Cessation of Dual Cigarette and E-cigarette Use

NCT06027840
View directory record Official record
Conditions
Cigarette Smoking, E-Cigarette Use, Smoking Cessation
Interventions
Varenicline, Counseling, Guided Self-Change Booklets
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 31, 2026, 8:31 AM EDT